WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the interview, Nayeema and Kara discuss their own experiences with diet fads and whether drugs like Wegovy and Ozempic will help America deal with the obesity epidemic or simply avoid tackling underlying issues like food supply, corporate greed and light regulation.
Questions? Comments? Email us at on@voxmedia.com or find us on Twitter @karaswisher and @nayeema
Learn more about your ad choices. Visit podcastchoices.com/adchoices

SHARE

COMMENT

VOICE_COMMENT

COMMENT_PAGE

CLAP

PICK

VOTE

It's on. Twice a week, award-winning journalist Kara Swisher gets to the heart of the story through no-holds-barred interviews with power players across business, tech, media, politics and beyond. So why do her guests show up? “Smart people,” says Kara, “like difficult questions.”
Mondays and Thursdays from New York Magazine and the Vox Media Podcast Network.